Pilot Study in the Treatment of Refractory Adenovirus (ADV) Infection with Related Donor ADV Cytotoxic T-Lymphocytes (ADV-CTLs) in Children, Adolescents and Young Adult Recipients

Phase: Recruiting

First Posted: October

Condition(s): Adenovirus (ADV)

NCT Number: NCT03266627 Other Study ID Number(s): NYMC 579-Adeno

What Is the Purpose of This Study?

The goal of this study is to find out if we can safely give the patient special immune cells called cytotoxic T-cells (CTLs). These cells are made from the patient’s stem cell donor's cells or a closely matched family donor and grown in the lab. These immune cells are designed to help fight adenovirus (ADV) infection.

Who Can Take Part in This Study?

  • Patients with adenovirus infections after an allogeneic stem cell transplant (HSCT) or those with primary immunodeficiencies, who have:
    • Rising adenovirus levels (increased by 10 times) after 7 days, or
    • Persistent adenovirus levels after 14 days, despite two weeks of proper anti-viral treatment, and/or
    • Ongoing symptoms caused by adenovirus, such as:
      • Lung infection (pneumonitis)
      • Bladder inflammation with bleeding (hemorrhagic cystitis)
      • Colon inflammation (colitis)
      • Liver inflammation (hepatitis)
      • Inability to tolerate anti-viral treatments due to side effects
  • Age: 0.1 to 30.99 years

For a full list of eligibility requirements, visit https://clinicaltrials.gov/study/NCT03266627

What Will Happen During This Study?

  • Patients will receive up to 5 infusions of CTLs.
  • The infusions will be given every 2 weeks.
  • Before, during and after treatment with the CTLs, they will have blood labs and assessments completed over multiple visits.

Principal Investigator

Rolla F. Abu-Arja
MD

Hematology & Oncology

Discover More Research
Explore additional studies relating to cell therapy